INT55418

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.61
First Reported 1994
Last Reported 2010
Negated 3
Speculated 2
Reported most in Abstract
Documents 29
Total Number 31
Disease Relevance 1.83
Pain Relevance 10.21

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (CYP2D6) small molecule metabolic process (CYP2D6) oxidoreductase activity (CYP2D6)
endoplasmic reticulum (CYP2D6)
Anatomy Link Frequency
plasma 5
liver 3
urine 2
hepatocytes 1
white blood cells 1
CYP2D6 (Homo sapiens)
Pain Link Frequency Relevance Heat
fluoxetine 18 100.00 Very High Very High Very High
Potency 9 100.00 Very High Very High Very High
Morphine 50 99.96 Very High Very High Very High
Oxycodone 10 99.84 Very High Very High Very High
Opioid 118 99.82 Very High Very High Very High
Dextromethorphan 37 99.56 Very High Very High Very High
Codeine 26 99.42 Very High Very High Very High
Duloxetine 134 99.36 Very High Very High Very High
tramadol 28 98.88 Very High Very High Very High
opiate 11 98.72 Very High Very High Very High
Disease Link Frequency Relevance Heat
Depression 68 97.80 Very High Very High Very High
Injury 2 95.32 Very High Very High Very High
Nicotine Addiction 11 92.28 High High
Death 11 85.36 High High
Cluster Headache 11 75.00 Quite High
Disease 21 72.92 Quite High
Constipation 51 72.40 Quite High
Headache 15 61.04 Quite High
Recurrence 63 57.80 Quite High
Pain 27 56.80 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In addition, different clinical trials conducted to study the effects of CYP3A4, CYP2D6, and MAO-A on the pharmacokinetics of almotriptan confirmed the involvement of these enzymes in the metabolic clearance of this drug and that no dose changes are required in the presence of inhibitors of these enzymes.
Regulation (effects) of CYP2D6
1) Confidence 0.61 Published 2003 Journal Drug Metab. Dispos. Section Abstract Doc Link 12642466 Disease Relevance 0.07 Pain Relevance 0.04
The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes.
Regulation (influence) of CYP2D6 associated with paracetamol
2) Confidence 0.59 Published 1994 Journal Pharmacogenetics Section Title Doc Link 7987405 Disease Relevance 0.43 Pain Relevance 0.19
The levels of other CYP proteins, including CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP2E1, were not affected by eletriptan.
Neg (not) Regulation (affected) of CYP2D6
3) Confidence 0.53 Published 2000 Journal Drug Metab. Dispos. Section Abstract Doc Link 10611140 Disease Relevance 0.06 Pain Relevance 0.15
The influence of CYP2D6 genotype and CYP2D6 inhibitors on enantiomeric plasma levels of tramadol and O-desmethyltramadol as well as response to tramadol was investigated.
Regulation (influence) of CYP2D6 in plasma associated with tramadol
4) Confidence 0.45 Published 2007 Journal Clin. Pharmacol. Ther. Section Abstract Doc Link 17361124 Disease Relevance 0 Pain Relevance 0.50
The influence of CYP2D6 genotype and CYP2D6 inhibitors on enantiomeric plasma levels of tramadol and O-desmethyltramadol as well as response to tramadol was investigated.
Regulation (influence) of CYP2D6 in plasma associated with tramadol
5) Confidence 0.45 Published 2007 Journal Clin. Pharmacol. Ther. Section Abstract Doc Link 17361124 Disease Relevance 0 Pain Relevance 0.50
The aim of the present study was to evaluate the influence of CYP2D6 and CYP2C9 genotypes on the plasma concentration of fluoxetine and norfluoxetine in psychiatric patients during steady-state conditions.
Regulation (influence) of CYP2D6 in plasma associated with fluoxetine
6) Confidence 0.45 Published 2004 Journal Eur. J. Clin. Pharmacol. Section Abstract Doc Link 14726986 Disease Relevance 0 Pain Relevance 0.36
Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions.
Regulation (Effect) of CYP2D6 in plasma associated with fluoxetine
7) Confidence 0.45 Published 2004 Journal Eur. J. Clin. Pharmacol. Section Title Doc Link 14726986 Disease Relevance 0 Pain Relevance 0.36
Pharmacokinetic work using probe drugs such as debrisoquine [11], first demonstrated the effects of CYP2D6 variants on drug metaboliser status.
Regulation (effects) of CYP2D6
8) Confidence 0.45 Published 2010 Journal Breast Cancer Res Section Body Doc Link PMC2949659 Disease Relevance 0 Pain Relevance 0.08
The objective of this study was to investigate whether CYP2D6 poor metabolizers (PM) and CYP2D6 extensive metabolizers (EM) would respond differently during testing for opiate drugs of abuse in urine after intake of these drugs.
Spec (whether) Regulation (respond) of CYP2D6 in urine associated with opiate
9) Confidence 0.44 Published 1997 Journal Ther Drug Monit Section Abstract Doc Link 9421105 Disease Relevance 0 Pain Relevance 0.61
The objective of this study was to investigate whether CYP2D6 poor metabolizers (PM) and CYP2D6 extensive metabolizers (EM) would respond differently during testing for opiate drugs of abuse in urine after intake of these drugs.
Spec (whether) Regulation (respond) of CYP2D6 in urine associated with opiate
10) Confidence 0.44 Published 1997 Journal Ther Drug Monit Section Abstract Doc Link 9421105 Disease Relevance 0 Pain Relevance 0.61
Consistent with this fact, CYP2D6 is effectively and completely reduced by a 5 mg mL?
Regulation (effectively) of CYP2D6
11) Confidence 0.44 Published 2007 Journal J Biol Inorg Chem Section Body Doc Link PMC2099460 Disease Relevance 0 Pain Relevance 0.03
Tramadol is an opioid drug metabolised in phase I by cytochrome P450 (CYP) enzymes, of which CYP2D6 is mainly responsible for the O-demethylation of tramadol, but is not involved in N-demethylation.
Regulation (responsible) of CYP2D6 associated with tramadol and opioid
12) Confidence 0.44 Published 2003 Journal Forensic Sci. Int. Section Abstract Doc Link 12893130 Disease Relevance 0.09 Pain Relevance 0.65
In vivo pharmacogenetic studies have indicated that the metabolism and disposition of haloperidol may be regulated by genetically determined polymorphic CYP2D6 activity.
Regulation (regulated) of CYP2D6
13) Confidence 0.44 Published 1999 Journal Clin Pharmacokinet Section Abstract Doc Link 10628896 Disease Relevance 0 Pain Relevance 0.15
The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone.
Regulation (effects) of CYP2D6 associated with oxycodone
14) Confidence 0.41 Published 2010 Journal Br. J. Pharmacol. Section Title Doc Link 20590587 Disease Relevance 0 Pain Relevance 0.27
CONCLUSIONS AND IMPLICATIONS: Drug-drug interactions via CYP2D6 and CYP3A affected oxycodone pharmacokinetics and its magnitude depended on CYP2D6 genotype.


Regulation (depended) of CYP2D6
15) Confidence 0.41 Published 2010 Journal Br. J. Pharmacol. Section Body Doc Link 20590587 Disease Relevance 0 Pain Relevance 0
The N-desmethylation pathway was indirectly affected by CYP2D6 phenotypic differences.
Regulation (affected) of CYP2D6
16) Confidence 0.40 Published 2007 Journal Pharmacol. Res. Section Body Doc Link 17175164 Disease Relevance 0 Pain Relevance 0
We conclude that nonspecific binding to microsomes of the inhibitor could affect the inhibitory potency against CYP2D6.
Regulation (affect) of CYP2D6 associated with potency
17) Confidence 0.39 Published 2005 Journal Biol. Pharm. Bull. Section Abstract Doc Link 15684471 Disease Relevance 0 Pain Relevance 0.54
Two aspects have been particularly taken into account: the changes or absence of changes in plasma/serum concentrations of concomitant drugs and the direct or indirect evidence of induction, inhibition or lack of effect on the six major human hepatic CYP isozymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4), as well as on other CYP isozymes or enzyme systems.
Regulation (effect) of CYP2D6 in plasma
18) Confidence 0.38 Published 2000 Journal Fundam Clin Pharmacol Section Abstract Doc Link 11030437 Disease Relevance 0 Pain Relevance 0.20
Methylnaltrexone is a weak inhibitor of CYP450 2D6 in vitro; however, in vivo, it has not affected the metabolism of the CYP2D6 substrate dextromethorphan.
Regulation (metabolism) of CYP2D6 associated with dextromethorphan
19) Confidence 0.37 Published 2010 Journal Core evidence Section Body Doc Link PMC2899781 Disease Relevance 0.61 Pain Relevance 0.51
Duloxetine is eliminated through hepatic metabolism involving CYP2D6 and CYP1A2.37

Duloxetine in acute treatment of major depression

Regulation (involving) of CYP2D6 associated with depression and duloxetine
20) Confidence 0.33 Published 2010 Journal Drug design, development and therapy Section Body Doc Link PMC2846146 Disease Relevance 0.47 Pain Relevance 0.97

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox